Distal renal tubular acidosis in children: what to do when alkali therapy has not normalised growth

Clinical Scenario

This protocol is for paediatric patients (under 18 years) with distal renal tubular acidosis who are already on alkali supplementation but continue to show persistent growth retardation — a defined failure of first-line management to achieve its growth and metabolic targets.

First-Line Treatment That Did Not Succeed

The preceding approach — alkali supplementation with paediatric dosing (potassium citrate or potassium bicarbonate) — targets maintenance of plasma bicarbonate, chloride, and potassium within age-appropriate ranges, alongside normalisation of growth and bone mineralisation. When these goals are not reached despite adequate alkali control, escalation to the next protocol is indicated.

Next-Step Approach (Partial Overview)

For children with persistent growth retardation despite adequate metabolic control on alkali therapy, the protocol introduces a specific recombinant hormone therapy — applied only in selected cases meeting defined criteria. The complete eligibility requirements, sequencing, and monitoring plan are contained in the structured protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1093/ndt/gfab171

We do not recommend the use of growth hormone in children with dRTA, unless there is persistent growth retardation despite adequate metabolic control.

View source ↗